Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04636814 · ClinicalTrials.gov registry record · Phase 3
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
A Phase 3 study, sponsored by Chiesi Farmaceutici S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,973
- Enrollment target
NCT04636814: Clinical Trial Phase 3 study, sponsored by Chiesi Farmaceutici S.p.A..
NCT04636814 is a Phase 3 study that was terminated before completion, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 3,973 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (415% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04636814, a Phase 3 study, was terminated before completion, sponsored by Chiesi Farmaceutici S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,973 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Primary Outcome
Moderate or severe exacerbation is defined by symptomatic worsening of COPD: * Moderate : requiring use of systemic corticosteroids (oral/IV/IM corticosteroids), and/or use of antibiotics * Severe : requiring hospitalisation or resulting in death
Interventions
- DRUG Placebo
- DRUG Roflumilast
- DRUG CHF6001 1600µg
- DRUG CHF6001 3200µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,973 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 3 |
Why NCT04636814 stopped before completion
NCT04636814 is an interventional study that assigns participants to a tested intervention. Its 3,973 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (415% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04636814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04636814 about?
NCT04636814 is a clinical study titled "A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)". The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
What is the current status of trial NCT04636814?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,973 participants. The study started on 2021-07-12. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT04636814?
The interventions under investigation include: Placebo (DRUG), Roflumilast (DRUG), CHF6001 1600µg (DRUG), CHF6001 3200µg (DRUG).
Who is sponsoring clinical trial NCT04636814?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04636814's enrollment target sits among peer trials
3,973 63rd of 2000 higher than 1,938 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI